Loading…
Arcutis Biotherapeutics, Inc. is projected to rise to $24.28 by 2027, a +15% move from its current price of $21.15. ARQT is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $20.56 | $21.16 | $21.78 | +0.06% |
| May 30 | $20.33 | $21.18 | $22.05 | +0.12% |
| May 31 | $20.16 | $21.19 | $22.27 | +0.18% |
| Jun 1 | $20.02 | $21.20 | $22.46 | +0.24% |
| Jun 2 | $19.89 | $21.21 | $22.62 | +0.31% |
| Jun 3 | $19.78 | $21.23 | $22.78 | +0.37% |
| Jun 4 | $19.68 | $21.24 | $22.92 | +0.43% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $19.68 | $21.24 | $22.92 | +0.43% |
| Week 2 | $19.16 | $21.33 | $23.75 | +0.86% |
| Week 3 | $18.78 | $21.42 | $24.44 | +1.29% |
| Week 4 | $18.48 | $21.51 | $25.05 | +1.72% |
| Week 5 | $18.23 | $21.61 | $25.61 | +2.16% |
| Week 6 | $18.01 | $21.70 | $26.14 | +2.60% |
| Week 7 | $17.82 | $21.79 | $26.65 | +3.04% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Arcutis Biotherapeutics, Inc. is a healthcare biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases. Its lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis.
It also develops ZORYVE foam for seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234 is a fusion protein that is a potent and highly selective checkpoint agonist of the CD200 receptor.
Arcutis Biotherapeutics, Inc. (ARQT) is a healthcare stock currently trading at $20.86 per share with a market cap of $2.61B. It ranks 1828 by market capitalization.
A major floor 21.2% below — a decisive break under it would weaken the trend.
The nearest floor, 7.8% below — buyers have tended to step in here.
The nearest ceiling, 16.2% above — a clean break opens room to run.
A major ceiling 35.1% above — clearing it would confirm fresh momentum.
Key ARQT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ARQT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $20.92 | Buy | $20.95 | Buy |
| MA 10 | $20.87 | Buy | $21.03 | Buy |
| MA 20 | $21.62 | Sell | $21.53 | Sell |
| MA 50 | $22.66 | Sell | $22.66 | Sell |
| MA 100 | $24.44 | Sell | $23.41 | Sell |
| MA 200 | $23.40 | Sell | $22.44 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 45.11 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | -30.60 | Neutral |
| Williams %R (14) | -24.66 | Info |
| MACD (12,26,9) | 0.04 | Buy |
| ROC (12) | -0.09 | Sell |
| Bollinger %B (20,2) | 0.41 | Neutral |
| Stochastic %K (14) | 75.34 | Neutral |
| TRIX (15) | -0.45 | Sell |
| Awesome (5,34) | -1.68 | Sell |
| Ultimate (7,14,28) | 42.95 | Neutral |
| Momentum (10) | 0.46 | Buy |
| Aroon Osc (25) | -36.00 | Sell |
| Hull MA (9) | 21.17 | Sell |
| ADX (14) | 15.10 | Neutral |
| ATR (14) | 0.55 | Info |
The 30-day technical picture is BEARISH. The RSI(14) is 40, while the 50-day simple moving average sits at $22.72 and the 200-day simple moving average at $23.34.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $19.50 | $21.15 | $29.13 | 0% | Neutral | |
| $19.16 | $24.28 | $32.66 | +15% | Neutral | |
| $19.66 | $25.64 | $35.80 | +21% | Bullish | |
| $21.62 | $28.89 | $41.54 | +37% | Bullish | |
| $23.88 | $32.59 | $48.05 | +54% | Bullish | |
| $28.42 | $39.57 | $59.61 | +87% | Bullish | |
| $31.49 | $44.65 | $68.60 | +111% | Bullish | |
| $32.15 | $46.37 | $72.52 | +119% | Bullish | |
| $32.44 | $47.56 | $75.61 | +125% | Bullish | |
| $32.11 | $47.82 | $77.18 | +126% | Bullish | |
| $49.68 | $79.49 | $136.72 | +276% | Bullish | |
| $81.93 | $148.42 | $280.04 | +602% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $19.50 | $21.15 | $25.01 | +0.00% |
| June 2026 | $18.93 | $22.25 | $26.81 | +5.22% |
| July 2026 | $18.85 | $22.36 | $27.32 | +0.48% |
| August 2026 | $18.85 | $22.52 | $27.81 | +0.70% |
| September 2026 | $19.42 | $23.34 | $29.08 | +3.64% |
| October 2026 | $19.47 | $23.51 | $29.53 | +0.75% |
| November 2026 | $18.84 | $22.86 | $28.91 | -2.78% |
| December 2026 | $18.78 | $22.88 | $29.13 | +0.11% |
Click any year to see its month-by-month ARQT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect ARQT to range from $19.50 to $29.13 through 2026. The $21.15 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The ARQT price prediction for 2027 points to an average of $24.28 (low $19.16, high $32.66) — a potential gain of +15% on today's $21.15. Price action looks broadly range-bound.
In 2028, ARQT is projected to trade between $19.66 and $35.80, averaging $25.64 — a potential gain of +21% from today's $21.15. That is up +6% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Arcutis Biotherapeutics, Inc.'s 2029 outlook centres on $28.89, within a $21.62 to $41.54 range. That is up +13% on the projected 2028 average. That marks a +37% change versus current levels. Momentum favours further upside here.
By 2030, ARQT could reach as high as $48.05, with a base case around $32.59 and support toward $23.88 — roughly +54% from $21.15. Buyers look set to stay in control over this stretch.
Expect ARQT to range from $28.42 to $59.61 through 2031. The $39.57 average target implies a +87% move from current prices. That is up +21% on the projected 2030 average. Momentum favours further upside here.
The ARQT price prediction for 2032 points to an average of $44.65 (low $31.49, high $68.60) — a potential gain of +111% on today's $21.15. Buyers look set to stay in control over this stretch.
In 2033, ARQT is projected to trade between $32.15 and $72.52, averaging $46.37 — a potential gain of +119% from today's $21.15. That is up +4% on the projected 2032 average. Momentum favours further upside here.
Arcutis Biotherapeutics, Inc.'s 2034 outlook centres on $47.56, within a $32.44 to $75.61 range. That is up +3% on the projected 2033 average. That marks a +125% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, ARQT could reach as high as $77.18, with a base case around $47.82 and support toward $32.11 — roughly +126% from $21.15. Momentum favours further upside here.
Expect ARQT to range from $49.68 to $136.72 through 2040. The $79.49 average target implies a +276% move from current prices. That is up +66% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The ARQT price prediction for 2050 points to an average of $148.42 (low $81.93, high $280.04) — a potential gain of +602% on today's $21.15. Momentum favours further upside here.
Investing $1,000 in ARQT today (≈ 47.281324 ARQT) could be worth
$7,017.55
+$6,017.55 (+602%) by 2050 · US Dollar
Based on the average projected ARQT price of $148.42 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ARQTwould be worth at today's price.
$1,000 invested in ARQT on May 27, 2025 (≈ 70.721356 ARQT) would be worth
$1,495.76
+$495.76 (+49.6%) today · 1.50× · US Dollar
Based on a ARQT entry price of $14.14 vs. today's $21.15.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $20.47 | $1,033.22 | +3.3% |
| 1 month ago | $23.42 | $903.07 | -9.7% |
| 3 months ago | $28.57 | $740.29 | -26.0% |
| 6 months ago | $30.65 | $690.05 | -31.0% |
| 1 year ago | $14.14 | $1,495.76 | +49.6% |
| All time (5.0y) ago | $27.42 | $771.33 | -22.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ARQT forecast.
Our base-case forecast reaches $42.00 around 2032.
Implied market cap at $42.00: $5.25B
The forecast spans 2026–2050 with a clear long-run uptrend. The 2026 avg price is $20.86, rising through 2030 to an avg of $32.25 and reaching an avg of $149.19 by 2050. The yearly forecast shows increasing upside, with 2027 avg $23.99, 2028 $25.11, 2029 $28.66, 2031 $39.30, 2032 $44.89, 2033 $45.97, 2034 $46.89, 2035 $47.69, 2040 $79.24, and 2050 $149.19.
ROI percentages accompany several years, including 2027 15, 2028 20.4, 2029 37.4, 2030 54.6, 2031 88.4, 2032 115.2, 2033 120.3, 2034 124.8, 2035 128.6, 2040 279.9, and 2050 615.2. The forecast is bullish from 2028 onward, with neutral outlook for 2026 and 2027.
Tap a question to reveal the answer.
The 2030 average price is $32.25 with a min of $23.35 and a max of $48.18, and a forecast ROI of 54.6. The sentiment is bullish for 2030.
The forecast shows upside potential with the average price rising from $20.86 in 2026 to $32.25 in 2030 and to $149.19 by 2050, with higher ROIs in later years. Sentiment shifts from neutral in 2026–2027 to bullish thereafter, but these are estimates and not guarantees.
Yes. The forecast projects an average of $79.24 by 2040, with $149.19 average by 2050, indicating that crossing $50 is anticipated by the longer term.
The 30-day range is $17.06 to $25.51.
The current price is $20.86 and the market cap is $2.61B.
Arcutis Biotherapeutics, Inc. Community Discussion
0Share your Arcutis Biotherapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.